The introduction of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable interest within the healthcare community. This groundbreaking dual GIP and GLP-1 receptor medication seems to offer notable improvements in body shedding compared to previous therapies. Preliminary clinical trial